Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Unity Biotechnology Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
UBX
Nasdaq
8731
https://unitybiotechnology.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Unity Biotechnology Inc
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
- Feb 6th, 2024 1:00 pm
10 Supplements for Longevity and Antiaging: Expert Recommendations
- Dec 29th, 2023 9:37 pm
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME
- Dec 12th, 2023 1:00 pm
Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky
- Nov 16th, 2023 11:37 am
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial ResultsĀ and Business Updates
- Nov 13th, 2023 9:05 pm
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
- Nov 10th, 2023 1:00 pm
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks
- Oct 17th, 2023 9:14 pm
20 Foods Consumed By Longest Living People Every Day
- Oct 4th, 2023 1:36 am
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
- Sep 27th, 2023 11:00 am
Unity Biotechnology Inc CEO Anirvan Ghosh Sells 1,246 Shares
- Sep 16th, 2023 5:02 am
20 States With The Longest Life Expectancy In America
- Aug 15th, 2023 8:51 pm
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates
- Aug 8th, 2023 8:05 pm
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
- Jun 21st, 2023 11:00 am
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial ResultsĀ and Business Updates
- May 9th, 2023 8:05 pm
Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea
- Apr 24th, 2023 5:34 pm
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
- Apr 24th, 2023 11:00 am
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
- Apr 23rd, 2023 10:00 pm
Scroll